We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Allure Labs Cited for Suspected Underreporting of Problematic OTC Drug Events, Testing Lapses
Allure Labs Cited for Suspected Underreporting of Problematic OTC Drug Events, Testing Lapses
The FDA issued over-the-counter (OTC) drug and cosmetic manufacturer Allure Labs a four-observation Form 483 following a November to December 2021 inspection of its Hayward, Calif., facility, noting procedural lapses and possible underreporting of deviations, nonconformances and out-of-specification (OOS) events.